← FDA DRUG APPROVALS

FDA NDA · NDA208401

QBRELIS

lisinopril

Sponsor: AZURITY

APPLICATION
NDA208401
TYPE
NDA
ORIGINAL APPROVAL
2016-07-29
LATEST ACTION
2017-07-28
ROUTE
ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

QBRELIS · ReferencePrescription
LISINOPRIL 1MG/ML · SOLUTION · ORAL

Approval history

2017-07-28Labeling · Supplement 2 · standardLabelAP
2016-07-29Type 3 - New Dosage Form · Original · standardReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →